MediciNova announced that Scientific Reports has published results from the animal model study evaluating MN-166, or ibudilast, in glioblastoma. The article, “Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor,” is the first publication reporting the potential clinical utility of MN-166 for GBM. Key findings in this publication include the following: In an in-vitro study using patient derived cell lines, MN-166 combined with temozolomide showed significant synergism in cell cycle arrest and apoptosis, and In an in-vivo patient derived xenograft model study, combination treatment with MN-166 and TMZ resulted in significantly longer overall survival. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased that these findings were published in Scientific Reports. These findings compelled us to open an IND application and evaluate MN-166 in a clinical trial of patients with GBM. Enrollment is ongoing at Dana-Farber Cancer Institute.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.